Novartis Venture Fund returned for the small molecule drug developer’s series B round, tipping its total funding to over $100m.
US-based small molecule drug developer Exo Therapeutics closed a $78m series B round yesterday featuring pharmaceutical firm Novartis, which invested through its Novartis Venture Fund.
Nextech Invest led the round, which included 6 Dimensions Capital – the life sciences investment firm co-founded by pharmaceutical firm WuXi AppTec, as well as Samsara Biocapital, BVF Partners, Casdin Capital, Morningside, Newpath Partners and CRV.
Exo is developing a pipeline of drugs aimed at using protein binding sites known as exosites to reprogramme enzyme…
Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
